Connection

Kathrin Jansen to Vaccines, Synthetic

Back to Details
This is a "connection" page, showing publications Kathrin Jansen has written about Vaccines, Synthetic.
Kathrin Jansen
Connection Strength
0.119
Vaccines, Synthetic
  1. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
    View in: PubMed
    Score: 0.022
  2. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
    View in: PubMed
    Score: 0.022
  3. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
    View in: PubMed
    Score: 0.022
  4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12 31; 383(27):2603-2615.
    View in: PubMed
    Score: 0.022
  5. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018 06; 17(6):461-477.
    View in: PubMed
    Score: 0.018
  6. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013 Apr; 32(4):364-71.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.